2023 Annual Meeting | C200 - Spinocerebellar and Spastic Ataxias: Diagnosis and Management

Date Thursday 04/27/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Oksana Suchowersky, MD, FAAN

Topic(s) Movement Disorders

Learning Objectives Participants will become familiar with the differential diagnoses, investigation, and management of patients with spinocerebellar and spastic ataxias. Particular attention will be given to benefits and limitations of genetic testing, update on pathophysiology, and potential for new and genetic therapies.

This program is supported in part by an educational grant from Reata Pharmaceuticals

The Academy was solely responsible, with no influence from the industry supporter, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporter with regard to this CME program.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Event Timeline
01:00 PM - 01:40 PM EST	Speaker	SCAs and Spastic Ataxias: Clinical Features and Diagnosis Oksana Suchowersky, MD, FAAN
01:40 PM - 02:20 PM EST	Speaker	Pathogenesis and New Therapeutic Options Massimo Pandolfo, MD, FAAN
02:20 PM - 03:00 PM EST	Discussion	Case Presentations and Discussion Oksana Suchowersky, MD, FAAN, Massimo Pandolfo, MD, FAAN

Faculty Disclosures
Oksana Suchowersky, MD, FAAN	Dr. Suchowersky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Syneos/Alexion. The institution of Dr. Suchowersky has received research support from Roche. The institution of Dr. Suchowersky has received research support from Wave LifeSciences. The institution of Dr. Suchowersky has received research support from CHDI. Dr. Suchowersky has received publishing royalties from a publication relating to health care. Dr. Suchowersky has received publishing royalties from a publication relating to health care.
Massimo Pandolfo, MD, FAAN	Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Minoryx. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Design Therapeutics . Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Reata. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biomarin. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design Therapeutics. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Pandolfo has stock in Voyager Therapeutics. The institution of Dr. Pandolfo has received research support from Freidreich Ataxaia Research Alliance. Dr. Pandolfo has a non-compensated relationship as a Scientific Advisory Board with Friedreich Ataxia Research Alliance that is relevant to AAN interests or activities. Dr. Pandolfo has a non-compensated relationship as a Member-Meeting Management Committee with AAN that is relevant to AAN interests or activities.